Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform... Read More

BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto. It allows us to keep our... Read More

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and... Read More

Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024 , on... Read More

Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission... Read More

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo... Read More

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation... Read More

BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly , is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT ( 1:30 p.m. ET ). Further details, a webcast link, and a replay of the presentation will be posted on the... Read More

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic... Read More

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity,... Read More

BOSTON , Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck , known as MSD outside of the United States and Canada , focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone... Read More

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON , Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024 , on Tuesday, November 12,... Read More

BOSTON and CHESTERFIELD, Mo. , Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to... Read More

BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA) , which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints... Read More

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON , Sept.... Read More

BOSTON , Sept. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the... Read More

BOSTON , Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk , is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET . Further details, a webcast link, and a replay of the... Read More

Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON , Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024 . The update, including a webcast slide... Read More

Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON , Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the... Read More

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON , Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024 , on Thursday, August 8, 2024 ,... Read More

Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution BASEL, Switzerland and BOSTON , July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading... Read More

BOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week : Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard , will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET... Read More

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a... Read More

Ginkgo's Class A Common Stock continues to trade on the NYSE BOSTON , May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc . (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it received a notice on May 7, 2024 from the New York Stock Exchange ("NYSE") informing the Company that it is not in compliance with Section 802.01C of the... Read More

Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON , May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity,... Read More

To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services , Protein Services , and Deployment Capabilities JONESBORO, Ark. and BOSTON , May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next... Read More

BOSTON , May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11 , in Baltimore, MD . Ginkgo will present three posters in cell... Read More

Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024 , on Thursday, May 9, 2024 ,... Read More

BOSTON , April 29, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of Myrtle Potter and Ross Fubini for election as independent directors at Ginkgo's upcoming annual meeting, scheduled to be held on June 13, 2024 . Marijn Dekkers, who has served on Ginkgo's Board since 2019 and as Ginkgo's Board Chair from 2019... Read More

BOSTON , April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference. The conference brings together stakeholders from across the synthetic biology community, including R&D leaders, Ginkgo Technology... Read More

BOSTON , April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated... Read More

BOSTON , April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years. Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D... Read More

Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation BOSTON , April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has been awarded a... Read More

Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil , April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Therapeutics... Read More

BOSTON , April 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment , on Thursday, April 11, 2024 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the... Read More

The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturing NORTHUMBERLAND, England and BOSTON , April 3, 2024 /PRNewswire/ -- Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming... Read More

BOSTON , April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for... Read More

BOSTON , March 28, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency ( DARPA ) to achieve DARPA's objectives under its new Ice... Read More

The partners will work to optimize AQUA Cultured Foods' fermentation technology and advance the development and production of AQUA's 100% fish-free products that emulate the look, feel, and taste of fresh-caught seafood CHICAGO and BOSTON , March 27, 2024 /PRNewswire/ -- AQUA Cultured Foods, a food tech company producing... Read More

Imagindairy and Ginkgo will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to economically produce non-whey dairy proteins for the food industry, funded in part by a competitively won joint grant by the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation HAIFA, Israel and BOSTON , March 26, 2024 /PRNewswire/ -- Imagindairy, an Israeli-based... Read More

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance (TGS) program to new collection locations... Read More

$251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma Year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency BOSTON , Feb.... Read More

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network partner, bit.bio’s ioCells™ portfolio of precision reprogrammed human cells for research and drug discovery will now be available within Ginkgo’s platform ecosystem. Integration of the ioCells research product portfolio could... Read More

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction with Patch Biosciences, Inc. ("Patch Bio") on February 26, 2024 , Ginkgo approved grants of restricted stock units with an aggregate grant date fair value of $4,292,000 to eight Patch Bio employees, and in connection with its... Read More

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models and four of Reverie's key AI team members will join... Read More

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for... Read More

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences , which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was... Read More

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D... Read More

The center will be a first of its-kind collection and analysis center for data gathered through Ginkgo's pathogen monitoring network DOHA, Qatar , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has announced today the signing of an agreement with Qatar Free Zones Authority (QFZ) and Doha Venture Capital (DVC) to build the first Center... Read More

BOSTON , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly , is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m. ET . The presentation details and webcast link will be available on Ginkgo's investor relations website at... Read More

Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024 BOSTON , Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023 , on Thursday, February 29, 2024 ,... Read More

BOSTON and LEXINGTON, Mass. , Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement... Read More

Members of Congress visited Ginkgo's Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in pharmaceuticals, agriculture, and across industries Ginkgo's Foundry generates essential data assets and tools to allow... Read More

KETCHUM, Idaho , Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States . With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the... Read More

This first milestone has made the full color palette of the yellow-to-purple spectrum accessible for Phytolon's food colors and has further established a unique and cost-efficient offering for the food industry Phytolon's natural betalain pigments, produced through fermentation-based technologies, offer safe, sustainable... Read More

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO , Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement... Read More

Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business Strong growth among blue chip pharma and biotech ("biopharma") customers including Pfizer, Novo Nordisk, Merck and Boehringer Ingelheim Management to highlight updates today at the 42nd... Read More

BOSTON , Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board. This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo's core platform service offerings across target discovery, drug discovery, optimization,... Read More

Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwide BOSTON , Jan. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the... Read More

BOSTON , Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly , is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT ( 12:45 p.m. ET ). The presentation details and webcast link will be available on Ginkgo's investor... Read More

OneOne is a French biotech startup developing a comprehensive suite of agricultural microbial solutions Ginkgo will support OneOne in its agricultural biologicals and synthetic biology R&D Ginkgo will initially conduct in vitro and in planta assays to test OneOne's concept. In a planned second phase, Ginkgo's Strain Optimization Services and ultra high throughput encapsulated screening will provide OneOne with optimized... Read More

The EIC has tapped FGen and partners to work on developing a sustainable, alternative approach to milk production using only CO 2 and electricity FGen will focus on ultra-high throughput screening of bacteria engineered to convert CO 2 into a major whey protein Utilizing microbial systems — instead of livestock — to produce... Read More

Algae-based biotechnology can be used to drive forward clean energy solutions, such as sustainable aviation fuel, yet scaling algal biotechnologies for such purposes faces major barriers The DOE has awarded a Ginkgo-led team — which also includes partners from Pacific Northwest National Laboratory, Colorado School of Mines ,... Read More

GreenLab is creating an enzymatic solution — to be grown and scaled within corn plants — to degrade PFAS, often called "forever chemicals," a major health and environmental concern Ginkgo has been tapped to discover and develop an enzyme that will be critical to the success of GreenLab's PFAS degradation application Through a... Read More

Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body Ginkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic... Read More

Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage Ginkgo's R&D services to further optimize Arbor's novel precision editors Arbor's portfolio of novel gene editors has significant therapeutic potential because of their unique protospacer adjacent motifs, varied... Read More

SÃO PAULO and BOSTON , Dec. 8, 2023 /PRNewswire/ -- Agrivalle , a leading Brazilian agricultural biologicals company, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Together, the companies will collaborate on building cutting edge technologies to advance Agrivalle's biological products, including next-gen fertilizers and... Read More

Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has entered into a non-binding Memorandum of Understanding ("MOU") with Ginkgo Bioworks with the intent to advance global DNA manufacturing and gene therapy platform services within the Japanese market Synplogen intends to support... Read More

Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation. Ginkgo will use its Protein Production Services and generative AI platform to deliver best-in-class candidate strains to Vivici. Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialised nutrition companies, to... Read More

Airport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue Growth Naples Wax Center Acquisition Accelerates Future Off-Airport Growth Opportunities Further Airport Spa Expansion Internationally NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023.... Read More

Foremost aims to commercialize a technology that can convert dairy manufacturing co-products into environmentally friendly, value-added materials The partners aim to reduce the dairy industry's carbon footprint while simultaneously lowering manufacturing costs and creating a significant new revenue stream for the hundreds of Midwest dairy farmer members comprising the Foremost Farms cooperative Foremost Farms will leverage... Read More

Ginkgo added 21 new Cell Programs to the Foundry platform in Q3 2023 Entered into strategic cloud and AI partnership with Google Cloud; first milestone recently achieved Signed new multi-target RNA drug discovery collaboration with Pfizer in which Ginkgo is eligible to receive research fees and development and commercial milestone payments of up to $331 million Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash... Read More

The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major U.S. airports BOSTON , Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work... Read More

Presentation and Q&A session scheduled for post-market on Wednesday, November 8, 2023 BOSTON , Nov. 1, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2023 , on Wednesday, November 8, 2023 , beginning at... Read More

The grant will fund research into more than 50 species of wildlife to better monitor for and prevent biological threats to humans BOSTON and UNIVERSITY PARK, Pa. , Oct. 24, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the... Read More

BELGRADE , Serbia and BOSTON , Oct. 19, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of Serbia today announced that they have entered into a Memorandum of Understanding ("MoU") with the intent of collaborating in support of... Read More

Persephone to utilize the Bacteroides technology for the rapid generation of therapeutics from its planned and ongoing biomarker studies, including the ARGONAUT study Ginkgo retains the rights to leverage the toolkit to address a wide range of customer needs and applications SAN DIEGO and BOSTON , Oct. 17, 2023 /PRNewswire/ --... Read More

BOSTON , Oct. 16, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Zenfold Sustainable Technologies, a company focused on developing and manufacturing specialty ingredients using sustainable technologies and precision fermentation, today... Read More

ZURICH, Switzerland and BOSTON , Oct. 12, 2023 /PRNewswire/ -- QL AG, an innovative food technology solutions company, today announced a new collaboration to develop dairy proteins with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. QL AG will tap into Ginkgo's extensive capabilities in strain engineering across multiple chassis organisms to support its goal of... Read More

Led by Northeastern University , the EPISTORM center will prepare local communities and hospitals for future outbreaks BOSTON , Oct. 5, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University , which has received a grant from the... Read More

BOSTON and BERLIN , Oct. 2, 2023 /PRNewswire/ -- Nosh.bio, a German startup developing highly functional ingredients from fungal biomass for animal-free food products, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Nosh.bio will... Read More

The grant will fund research of white-tailed deer to evolve knowledge of spillover events and support efforts to design an early warning system for biological threats BOSTON and COLLEGE STATION, Texas , Sept. 29, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Texas A&M University today announced they have been jointly awarded a research grant... Read More

BOSTON , Sept. 28, 2023 /PRNewswire/ -- Ensovi Inc., which has invented an efficient, cell-free biomanufacturing platform that transforms waste CO 2 to organic chemicals, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Ensovi will... Read More

BOSTON , Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across... Read More

ANTANANARIVO, Madagascar and BOSTON , Sept. 25, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of the Republic of Madagascar today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Madagascar . Ginkgo's biosecurity unit,... Read More

SAN CARLOS, Calif. and BOSTON , Sept. 18, 2023 /PRNewswire/ -- Factorial Biotechnologies, an emerging single-cell sequencing company with a novel intracellular library preparation technology, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration. Through this partnership, Factorial will leverage Ginkgo Enzyme Services to develop a... Read More

MANASSAS, Va. and BOSTON , Sept. 12, 2023 /PRNewswire/ -- Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and... Read More

BOSTON , Sept. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that Anna Marie Wagner , Senior Vice President of Corporate Development, is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13 at 12:55 p.m. ET . Further... Read More

SANTIAGO, Chile and BOSTON , Aug. 31, 2023 /PRNewswire/ -- Exacta Bioscience, a biotech company that harnesses the power of nature and its microorganisms for crop protection, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Exacta is leveraging Ginkgo's end-to-end agricultural R&D services to run a fermentation optimization and scale-up program... Read More

BOSTON , Aug. 30, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it will hold an Investor Day on Tuesday, October 3, 2023 , beginning at 10:00 am ET . The event will feature conversations with Ginkgo's founders and senior management team across both its cell engineering and biosecurity businesses.... Read More

Ginkgo and Google Cloud enter strategic five-year cloud and AI partnership Ginkgo to pioneer new large language models for biological engineering applications, powered by Google Cloud's Vertex AI platform Ginkgo intends to make Google its primary cloud services provider, benefiting from access to next-generation computational infrastructure and AI technologies Partnership to include funding from Google Cloud to enable... Read More

This collaboration aims to develop and deploy novel methods for pandemic surveillance among animals and livestock BOSTON and NAIROBI, Kenya , Aug. 24, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading horizontal platform for cell programming and biosecurity, and the International Livestock Research Institute (ILRI), a leading organization on One Health approaches, today announced that they have... Read More

BOSTON , Aug. 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a panel discussion titled " Generative AI & Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine " at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15... Read More

Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as Ginkgo continues to drive towards profitability BOSTON , Aug. 9, 2023... Read More

BOSTON , Aug. 7, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada , focused on improving biologic manufacturing. Ginkgo will apply its expertise and... Read More

BOSTON and PANAMA CITY, Panama , Aug. 3, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America.... Read More

Presentation and Q&A session scheduled for post-market on Wednesday, August 9, 2023 BOSTON , Aug. 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2023 , on Wednesday, August 9, 2023 , beginning at 5:30 p.m.... Read More

ARLINGTON, Va. and BOSTON , July 19, 2023 /PRNewswire/ -- Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency ( DARPA ) announced that Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a 4-year contract... Read More

TOKYO and BOSTON , July 18, 2023 /PRNewswire/ -- Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership. Sumitomo Chemical and Ginkgo... Read More

BOSTON and GABORONE, Botswana , July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2. Through this program, Ginkgo's biosecurity and... Read More

BOSTON , July 13, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a research contract from the Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence Community, for the Biointelligence and Biosecurity for the Intelligence Community (B24IC) program. Through this program,... Read More

BOSTON , July 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for... Read More

Ambrosia aims to make the production of allulose, a next-generation sugar replacement, more scalable and affordable JERUSALEM and BOSTON , June 29, 2023 /PRNewswire/ -- Ambrosia Bio, an Israeli foodtech company developing novel bioprocesses for the global sugar replacement industry, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ambrosia Bio... Read More

LOS ANGELES and BOSTON , June 28, 2023 /PRNewswire/ -- Voodoo Scientific, a company creating capabilities to help distillers deliver meaningful innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced Voodoo's plans to leverage Ginkgo Enzyme... Read More

The report, Caring at Ginkgo , demonstrates Ginkgo's commitment and contributions to environmental, societal and governance matters BOSTON , June 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today published its 2022 Sustainability Report, Caring at Ginkgo , detailing the company's views and progress towards addressing global challenges,... Read More

By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, AgBiome aims to unlock even higher performance of its microbial strain pipeline RESEARCH TRIANGLE PARK, N.C. and BOSTON , June 6, 2023 /PRNewswire/ -- AgBiome ® , Inc., a leader in global microbial innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a... Read More

BOSTON , June 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference, on June 12, 2023 , at 4:40 p.m. PT . Further details, a webcast link, and a replay of the fireside chat will be... Read More

RIJSWIJK, Netherlands and BOSTON , May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio... Read More

Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023 Recent acquisition of the adeno-associated virus (AAV) capsid engineering platform assets of StrideBio is advancing Ginkgo's capabilities and commercial potential in gene therapy Ginkgo ended Q1 2023 with approximately $1.2 billion in cash and cash equivalents - this strong balance sheet is a strategic asset that provides Ginkgo with a multi-year runway and... Read More

COPENHAGEN, Denmark and BOSTON , May 9, 2023 /PRNewswire/ -- Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in... Read More

BOSTON , May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development... Read More

Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories Marie Fallon to step down as CAO effective May 15, 2023 BOSTON , May 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and... Read More

BOSTON , May 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20 , in Los Angeles . Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of... Read More

Presentation and Q&A session scheduled for post-market on Wednesday, May 10, 2023 BOSTON , May 3, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2023 , on Wednesday, May 10, 2023 , beginning at 4:30 p.m. ET.... Read More

Partnership aims to enable cost-effective decarbonization of rubber tire manufacturing and sustainable aviation fuel production HAYWARD, Calif. and BOSTON , April 24, 2023 /PRNewswire/ -- Visolis, a company combining advanced bioengineering with chemical catalysis to provide sustainable, carbon-negative materials, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell... Read More

BOSTON , April 19, 2023 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment . The conference brings together stakeholders from across the synthetic biology community, including customers, suppliers, academics, journalists, and many more. Because the event has reached its in-person capacity limits, a... Read More

BERLIN and BOSTON , April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of... Read More

Partnership will leverage Ginkgo's cell programming capabilities to support Syngenta's ongoing seeds R&D pipeline efforts BOSTON , April 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds ("Syngenta"), one of the world's leading agricultural technology companies, today announced a research partnership focused on screening a... Read More

BOSTON and KINSHASA , Democratic Republic of the Congo , April 14, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading horizontal platform for cell programming and biosecurity, and the Institut National de la Recherche Biomédicale ("INRB"), the national medical research organization of the Democratic Republic of the Congo ("DRC"), today announced that they have entered into a Memorandum of... Read More

Collaboration with University of Wisconsin Professors Krishanu Saha (PI) and Christian Captini (co-PI) to discover novel and improved GD2 CAR designs to treat solid tumors and validate them in vivo MADISON, Wis. and BOSTON , April 13, 2023 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison , and Ginkgo Bioworks (NYSE: DNA), which... Read More

BOSTON , April 12, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment , on Wednesday, April 19, 2023 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the Ginkgo community, from shareholders and customers to suppliers, academics, and many more. Because... Read More

Sensible Biotechnologies aims to build a cell-based platform for cost-efficient and scalable manufacturing of high-quality mRNA. Proceeds will be used to optimize and scale Sensible's mRNA manufacturing platform and mRNA design capabilities. The pre-seed funding led by BlueYard Capital follows Sensible's announcement of a strategic partnership with Ginkgo Bioworks (NYSE: DNA). OXFORD, England , April 6, 2023 /PRNewswire/ --... Read More

Platform includes large library of existing capsids, which have been optimized for performance and targeting across a range of application areas through validation in large animal models The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid,... Read More

The investment will accelerate the development of new sustainable biopolymers, strengthening Solvay's position in biotechnology in this important growth platform. BRUSSELS and BOSTON , April 4, 2023 /PRNewswire/ -- Solvay , a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the... Read More

Through this partnership, Sensible and Ginkgo aim to develop an in vivo alternative to conventional in vitro mRNA production technology OXFORD, United Kingdom , April 3, 2023 /PRNewswire/ -- Sensible Biotechnologies , an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell... Read More

BOSTON , March 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in Cowen's 43 rd Annual Health Care Conference, including: Fireside chat on Monday, March 6, 2023 , at 9:10 a.m. ET SynBio & AI Driven Drug Discovery panel on Monday, March 6, 2023 , at 4:40 p.m. ET... Read More

$478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we drive towards profitability BOSTON , March 1, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA,... Read More

Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash... Read More

Ginkgo will develop and optimize strains to produce functional oligosaccharides for NAMUH's infant nutrition products BOSTON , Jan. 18, 2023 /PRNewswire/ -- NAMUH, an infant nutrition company, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those... Read More

The collaboration will launch a pilot program for wastewater-based pathogen monitoring to support critical public health needs BOSTON and KYIV, Ukraine , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Public Health Center of the Ukraine Ministry of Health today announced a new collaboration to conduct a wastewater testing pilot... Read More

The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airports BOSTON and NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program to... Read More

Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and puts Ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment Strong growth among biopharma customers as Ginkgo has scaled its mammalian cell engineering capabilities, including recently opening Bioworks7,... Read More

LONDON and BOSTON , Jan. 9, 2023 /PRNewswire/ -- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics. Most gene therapies today leverage viral delivery systems. While... Read More

Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications BOSTON , Jan. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its... Read More

Initial focus of partnership will aim to develop cancer therapeutics PLYMOUTH, Mich. and BOSTON , Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. Initially, Ginkgo and... Read More

BOSTON , Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m. PT ( 2:15 p.m. ET ). He plans to discuss Ginkgo's biopharma capabilities and end-to-end services offerings,... Read More

Collaboration aims to leverage innovative biosecurity capabilities to promote public health, global health security, and the development of the bioeconomy BOSTON and GABORONE, Botswana , Dec. 20, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH"), representing the Government of the Republic of Botswana , today... Read More

Enzyme Intelligence Virtual Event on December 15, 2022 gives overview of Ginkgo's approach to machine learning-guided enzyme engineering BOSTON , Dec. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme... Read More

BOSTON , Dec. 2, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with Bayer CropScience LP ("Bayer") on October 17, 2022 , Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. ("Zymergen") on... Read More

15 new Cell Programs added and $66 million of Total revenue in Q3 2022 Closed four acquisitions in October, including Zymergen and Bayer's West Sacramento agricultural biologicals capabilities, enabling commencement of integration and pursuit of new growth opportunities End of quarter cash balance of over $1.3 billion provides continued financial flexibility BOSTON , Nov. 14, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings,... Read More

Collaboration aims to bolster capabilities of key public health and research institutions, launch new biosecurity initiatives, and drive the development of the bioeconomy Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Ministry of Investment of Saudi Arabia ("MISA"), representing the Kingdom of Saudi Arabia , today announced that they have entered into a non-binding Memorandum of... Read More

Program builds on the existing relationship between the partners following existing b-silk™ protein optimization project Bolt Threads , a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio... Read More

Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks... Read More

The Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence community, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and Draper, a nonprofit engineering innovation firm, today announced the completion of IARPA's Finding Engineering-Linked Indicators ( FELIX) program . The program was created to augment and improve current... Read More

Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Merck, known as MSD outside the United States and Canada , to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Through this... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality. The Circularis platform also allows ultra-high-throughput screening of promoters and... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform. A fleet of Altar's automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo's Foundry to serve customers across food and beverage, biofuels, biomaterials, cosmetics,... Read More

The White House today announced that President Biden intends to appoint Renee Wegrzyn , PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi , Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools. In this new role, Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities. Dr. Mahdavi brings more than 20 years... Read More

Transaction is expected to bolster Ginkgo's growing biosecurity platform and provide expanded epidemic tracking, modeling, and forecasting offerings to public health leaders and communities Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware -based public benefit corporation. Under... Read More

$145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new Cell Programs added in Q2 2022, representing 86% growth over Q2 2021 Pending acquisitions of Zymergen and Bayer's West Sacramento agricultural biologicals capabilities expected to enable new growth opportunities in the coming years Approximately $1.4 billion cash balance provides continued multi-year runway as Ginkgo drives towards... Read More

Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expected to support public health and biosecurity services totaling approximately $16 million, with an overall potential to exceed $61... Read More

Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention's (CDC's) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022 . The... Read More

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the... Read More

Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda , today announced that they have entered into a Memorandum of Understanding ("MOU") with... Read More

Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022 Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022 , on Monday, August 15, 2022 , beginning at 4:30 p.m. ET . The presentation details and webcast link will be available... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan , PhD, CPA has joined its Board of Directors, effective August 2, 2022 . Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives. "As a pioneer in... Read More

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end markets Zymergen's... Read More

Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage... Read More

The report, "Caring at Ginkgo," outlines the company's approach to sustainability, internal governance structures, and how its cell engineering platform is deployed Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report . The report highlights the company's vision for and approach to sustainability, includes case studies across its ecosystem, and... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43 rd Annual Global Healthcare Conference, on June 15, 2022 , at 10:40 a.m. PT . Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk , a leading global healthcare company, to create novel expression hosts for pharmaceutical products. Today, hundreds of millions of people are living with diabetes, obesity, and other serious chronic diseases, putting a strain on individuals, families, and healthcare systems. More effective... Read More

Through real-time metabolite monitoring, Bitome's technology is expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has... Read More

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42 nd Annual Growth Stock Conference, on June 9, 2022 , at 11:20 a.m. CT . Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.... Read More

Partnership recognizes the importance of global cooperation to prevent and respond to pandemics By leveraging Ginkgo's large-scale biosecurity platform and Qatar's pioneering investments in biotechnology, collaboration aims to build new biosecurity capabilities and accelerate the establishment of a global pathogen monitoring network Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First... Read More

$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021 11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021 Increasing full year guidance for Total revenue from $325 – $340 million to $375 – $390 million , reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance Recently announced plans to expand platform capabilities in agricultural biologicals... Read More

Evo Foods will leverage Ginkgo's cell engineering capabilities to explore recombinant production methods for egg proteins Evo Foods , a consumer packaged goods company creating the next generation of plant-based substitutes for animal products, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell... Read More

Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022 Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022 , on Monday, May 16,... Read More

Planned transaction expands Ginkgo's horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry Under the proposed transaction, Ginkgo to acquire Bayer's West Sacramento agricultural biologicals site and team, adding a 175,000-square-foot R&D facility with pilot scale... Read More

Leveraging Ginkgo's plant-cell assay and engineering capabilities to aid Light Bio in optimizing the performance of its light-emitting plants Light Bio, Inc. , a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today... Read More